Erdi Bazhen decoction for cancer-related fatigue due to qi and blood deficiency in prostate cancer patients receiving androgen deprivation therapy: an exploratory randomized, double-blind, placebo-controlled pilot clinical trial protocol
- 1The Urology and Andrology Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China
- 2Department of Urology, Deyang Hospital Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Deyang, Sichuan, China
Abstract
Background: Prostate cancer is the most common male genitourinary malignancy in China. Long-term androgen deprivation therapy (ADT) causes severe cancer-related fatigue (CRF), which impairs patients’ physical function and quality of life. Currently, there is a lack of safe, long-term specific pharmacological agents for this condition in Western medicine. From the perspective of traditional Chinese medicine (TCM), qi and blood deficiency is the core pathogenesis underlying the occurrence and progression of CRF. Erdi Bazhen Decoction (EBD) has shown favorable clinical effects on fatigue after ADT in routine practice, but high-quality clinical evidence remains scarce, and key parameters for large-scale confirmatory trials remain undetermined. This exploratory pilot trial aims to investigate the preliminary efficacy and safety of EBD granules for CRF in prostate cancer patients receiving ADT, and to estimate critical trial parameters including effect size, recruitment rate, adherence and dropout rate to inform the design of a future large-scale confirmatory RCT.
Methods: This single-center, prospective, randomized, double-blind, placebo-controlled parallel pilot trial will enroll 50 eligible patients from a single hospital. Participants will be randomly assigned to two groups at a 1:1 ratio. Both groups will receive routine supportive care for 4 weeks. The intervention group will receive EBD granules, and the control group will receive matched placebo granules. The primary exploratory efficacy endpoint is the change in total score of the revised Piper Fatigue Scale (PFS-R) from baseline to week 4. Secondary outcomes include quality of life, physical performance and TCM syndrome scores; hemoglobin and C-reactive protein levels will be assessed as exploratory biomarkers. Trial feasibility parameters such as recruitment rate, medication adherence and dropout rate will also be descriptively analyzed to inform future trial design. Safety indicators and adverse events will be fully recorded. Variable block randomization without stratification and full double-blinding will be implemented. The primary analysis will be conducted in the intention-to-treat population; a per-protocol analysis will be performed as a sensitivity analysis. All efficacy estimates are exploratory. This protocol was designed in accordance with the SPIRIT 2025 statement; trial results will be reported in accordance with the CONSORT 2025 statement.
Conclusion: This standardized pilot controlled trial will provide preliminary clinical evidence and essential methodological parameters for EBD in relieving ADT-related fatigue. The results may offer preliminary support for a safe TCM regimen to improve patients’ fatigue, physical status and quality of life, and lay a methodological foundation for integrated Chinese and Western medicine management of prostate cancer-related fatigue. As an exploratory pilot study, the single-center design, small sample size and short intervention period limit the generalizability of confirmatory conclusions. Further large-scale, multi-center, long-term confirmatory trials are needed to verify the long-term effects and population applicability of EBD.
Clinical Trial Registration: https://itmctr.ccebtcm.org.cn/, identifier [ITMCTR2026001527].
Related
- mHealth-based lifestyle intervention for hypertension in community-dwelling adults: a cluster-randomized controlled trial with exploratory multi-omics analyses
- Effects of Probiotic Supplementation on Performance Retention During Detraining and Recovery After Simulated Return-to-Training Stress in College Volleyball Players: An Exploratory Randomized, Single-Blind, Placebo-Controlled Trial
- Comparative outcomes of conventional follitropin delta 15 µg/day versus follitropin alfa 225 IU/day for ovarian stimulation: results from an exploratory post hoc analysis of Spanish participants from the ADAPT-1 randomized controlled trial
- Reduced-dose alternate-day oral iron supplementation in women with iron deficiency: a randomized controlled trial
- A Kampo medicine, kamishoyosan, ameliorates menstruation-associated symptoms in patients with premenstrual syndrome: An exploratory open-label, randomized controlled trial
BibTeX
@article{wei2026erdi,
title = {{Erdi Bazhen decoction for cancer-related fatigue due to qi and blood deficiency in prostate cancer patients receiving androgen deprivation therapy: an exploratory randomized, double-blind, placebo-controlled pilot clinical trial protocol}},
author = {Jintao Wei and Jian Ma and Ziyang Ma and Yang Liu and Lei Xu and Xuefeng Mei and Peihai Zhang},
journal = {Frontiers in Medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1970591},
url = {https://doi.org/10.3389/fmed.2026.1970591},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Erdi Bazhen decoction for cancer-related fatigue due to qi and blood deficiency in prostate cancer patients receiving androgen deprivation therapy: an exploratory randomized, double-blind, placebo-controlled pilot clinical trial protocol
AU - Jintao Wei
AU - Jian Ma
AU - Ziyang Ma
AU - Yang Liu
AU - Lei Xu
AU - Xuefeng Mei
AU - Peihai Zhang
PY - 2026
DA - 2026/10/13
JO - Frontiers in Medicine
DO - 10.3389/fmed.2026.1970591
UR - https://doi.org/10.3389/fmed.2026.1970591
AB - Background: Prostate cancer is the most common male genitourinary malignancy in China. Long-term androgen deprivation therapy (ADT) causes severe cancer-related fatigue (CRF), which impairs patients’ physical function and quality of life. Currently, there is a lack of safe, long-term specific pharmacological agents for this condition in Western medicine. From the perspective of traditional Chinese medicine (TCM), qi and blood deficiency is the core pathogenesis underlying the occurrence and progression of CRF. Erdi Bazhen Decoction (EBD) has shown favorable clinical effects on fatigue after ADT in routine practice, but high-quality clinical evidence remains scarce, and key parameters for large-scale confirmatory trials remain undetermined. This exploratory pilot trial aims to investigate the preliminary efficacy and safety of EBD granules for CRF in prostate cancer patients receiving ADT, and to estimate critical trial parameters including effect size, recruitment rate, adherence and dropout rate to inform the design of a future large-scale confirmatory RCT. Methods: This single-center, prospective, randomized, double-blind, placebo-controlled parallel pilot trial will enroll 50 eligible patients from a single hospital. Participants will be randomly assigned to two groups at a 1:1 ratio. Both groups will receive routine supportive care for 4 weeks. The intervention group will receive EBD granules, and the control group will receive matched placebo granules. The primary exploratory efficacy endpoint is the change in total score of the revised Piper Fatigue Scale (PFS-R) from baseline to week 4. Secondary outcomes include quality of life, physical performance and TCM syndrome scores; hemoglobin and C-reactive protein levels will be assessed as exploratory biomarkers. Trial feasibility parameters such as recruitment rate, medication adherence and dropout rate will also be descriptively analyzed to inform future trial design. Safety indicators and adverse events will be fully recorded. Variable block randomization without stratification and full double-blinding will be implemented. The primary analysis will be conducted in the intention-to-treat population; a per-protocol analysis will be performed as a sensitivity analysis. All efficacy estimates are exploratory. This protocol was designed in accordance with the SPIRIT 2025 statement; trial results will be reported in accordance with the CONSORT 2025 statement. Conclusion: This standardized pilot controlled trial will provide preliminary clinical evidence and essential methodological parameters for EBD in relieving ADT-related fatigue. The results may offer preliminary support for a safe TCM regimen to improve patients’ fatigue, physical status and quality of life, and lay a methodological foundation for integrated Chinese and Western medicine management of prostate cancer-related fatigue. As an exploratory pilot study, the single-center design, small sample size and short intervention period limit the generalizability of confirmatory conclusions. Further large-scale, multi-center, long-term confirmatory trials are needed to verify the long-term effects and population applicability of EBD. Clinical Trial Registration: https://itmctr.ccebtcm.org.cn/, identifier [ITMCTR2026001527].
SN - 2296-858X
ER -